Press Releases
Pharmspective Releases New Pipeline Perspectives Reports in Key Autoimmune Diseases
FOR IMMEDIATE RELEASE
New York, NY, July 25, 2012 – Pharmspective, LLC, the specialty therapeutics market research firm, announced today the release of its two newest syndicated market research reports, Rheumatoid Arthritis Pipeline Perspectives, and Psoriasis Pipeline Perspectives
These new Pharmspective reports coincide with a number of key milestones in Rheumatoid Arthritis (RA) & Psoriasis product development:
- Tofacitinib 2nd line recommended approval for moderate-severe RA by an FDA Advisory Panel (Pfizer)
- Successful Phase III study completion of a Remicade Biosimilar (CT-P13; Celltrion)
- Promising early-stage data in RA from an oral JAK-1 inhibitor (GLPG0634; Galapagos)
A New Standard in Syndicated Research on Pharma Product Development Pharmspective’s Pipeline Perspectives reports are unique in that they are the first Pipeline study to analyze drugs in development for a therapeutic pathway by pathway or mechanism of action rather than by clinical development phase. This dynamic approach creates a framework for understanding product development strategies of future competitors and the impact of potential product approvals on the standard-of-care. The extensive detail in each report about the clinical trial results of pipeline drugs provides a blueprint for new product planning and a critical strategic input for future marketing of established therapies.
“The structure of our analyses sets a new standard for pipeline assessments that go beyond simple lists of drugs in development by phase,” stated Katie Derdeyn, M.D., Managing Partner and Co-Founder. “Pipeline Perspectives are different – we structure our analysis by pathway or mechanism of action to generate a strategic perspective on what competitive scenarios will likely define the future composition of each market.”
Pipeline Analysis by Pathway Target and Mechanism of Action
Reasons to Purchase Pipeline Perspectives Reports
- Unlike many pipeline databases, our vetting process eliminates drugs that have been discontinued for development from the analysis, saving you significant time and effort
- Comprehensive segmentation of disease pathway targets currently under investigation
- Comprehensive explanation of how the product development efforts of specific companies are focused (e.g., IL-6, IL-12, etc.)
- Assessment of how the drugs in development compare to drugs either on the market, in development in the same pathway, or relative to different mechanisms-of-action, based on clinical trial data
- Timing of product launches of drugs in development, if approved
- Detail around licensing terms for drugs in development, if applicable
Let us do the heavy lifting!
We connect the dots across the Healthcare Ecosystem from lots of different sources to make your job easier for you, the healthcare decision-maker. You already have enough to worry about. We want you to think about solutions to big problems, not about how to find data to answer questions.